Advertisement

Topics

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2015

05:00 EDT 8 Jun 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-04-28. This 81-page report is available in PDF from $2000.

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2015’, provides an overview of the Basal Cell Carcinoma (Basal Cell Epithelioma)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Basal Cell Carcinoma (Basal Cell Epithelioma)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Basal Cell Carcinoma (Basal Cell Epithelioma) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Basal Cell Carcinoma (Basal Cell Epithelioma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Basal Cell Carcinoma (Basal Cell Epithelioma) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and…

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Basal Cell Carcinoma (Basal Cell Epithelioma) Overview 8
Therapeutics Development 9
Pipeline Products for Basal Cell Carcinoma (Basal Cell Epithelioma) - Overview 9
Pipeline Products for Basal Cell Carcinoma (Basal Cell Epithelioma) - Comparative Analysis 10
Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics under Development by Companies 11
Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics under Investigation by Universities/Institutes 12
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Basal Cell Carcinoma (Basal Cell Epithelioma) - Products under Development by Companies 16
Basal Cell Carcinoma (Basal Cell Epithelioma) - Products under Investigation by Universities/Institutes 17
Basal Cell Carcinoma (Basal Cell Epithelioma) - Companies Involved in Therapeutics Development 18
4SC AG 18
Biofrontera AG 19
Biogenomics Limited 20
Biosceptre International Limited 21
Bristol-Myers Squibb Company 22
Genextra S.p.a. 23
MediGene AG 24
Novartis AG 25
Oncovir, Inc. 26
Redx Pharma Ltd 27
Transgene SA 28
Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Combination Products 30
Assessment by Target 31
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
aminolevulinic acid hydrochloride - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
BIL-010t - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
BMS-833923 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
CIGB-128 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
CS-S/BCC-1 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
CS-TATI-1 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
DAC-060 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
erismodegib - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
interferon alfa-2b (recombinant) - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
LEQ-506 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Oshadi D + Oshadi R - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Poly-ICLC - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55 For more information open Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2015.

SKU: GMDHC6613IDB

Original Article: Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2015

NEXT ARTICLE

More From BioPortfolio on "Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2015"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Skin cancers
There are three main types of skin cancer: basal cell carcinoma, squamous cell carcinoma and malignant melanoma. Basal cell carcinoma Basal cell carcinoma, or BCC, is a cancer of the basal cells at the bottom of the epidermis. It’s very common ...